Clene Announces $4 Million Registered Direct Offering
Clene Inc., a clinical-stage biopharmaceutical company listed on Nasdaq, announced a registered direct offering of approximately 1.22 million shares priced at $3.28 per share, raising $4 million from existing shareholders including insiders. The proceeds are expected to fund the company's operations and regulatory efforts through mid-first quarter …